Data requirements for adjuvants in vaccines for veterinary use - Scientific guideline
Table of contents
The aim of the guideline is to outline the information which should be included for an adjuvant in the marketing authorisation application (MAA) dossier of veterinary vaccines as required in Section IIIb of the Commission Delegated Regulation (EU) 2021/805 amending Annex II to Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products (repealing Directive 2001/82/EC). This guideline replaces the ‘Note for Guidance on the use of adjuvanted veterinary vaccines’ (EMA/CVMP/IWP/043/97).
Keywords: Adjuvant, Immunological Veterinary Medicinal product (IVMP), EMA, IWP
-
List item
Overview of comments received on 'Draft guideline on the use of adjuvanted veterinary vaccines - Revision 1' (PDF/436.06 KB)
First published: 23/07/2021
EMA/CVMP/IWP/30398/2019 -
List item
Draft guideline on the use of adjuvanted veterinary vaccines - Revision 1 (PDF/181.05 KB)
Draft: consultation closed
First published: 05/07/2018
Last updated: 05/07/2018
Consultation dates: 05/07/2018 to 15/01/2019
EMA/CVMP/IWP/315887/2017 -
List item
Concept paper for the revision of the note for guidance on the use of adjuvanted veterinary vaccines - Revision 1 (PDF/85.65 KB)
Draft: consultation closed
First published: 28/09/2016
Last updated: 28/09/2016
Consultation dates: 28/09/2016 to 31/12/2016
EMA/CVMP/IWP/867395/2015 -
List item
Note for guidance on the use of adjuvanted veterinary vaccines - First version (PDF/42.43 KB)
Adopted
First published: 01/11/1996
Last updated: 01/11/1996
Legal effective date: 01/12/1998
CVMP/IWP/043/97-FINAL